NuCana plc (NCNA)
- Previous Close
3.6300 - Open
3.8500 - Bid --
- Ask --
- Day's Range
3.5300 - 3.8500 - 52 Week Range
3.4000 - 23.7500 - Volume
6,523 - Avg. Volume
84,704 - Market Cap (intraday)
8.227M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-16.2200 - Earnings Date Aug 14, 2024 - Aug 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
125.19
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
www.nucana.comRecent News: NCNA
Performance Overview: NCNA
Trailing total returns as of 5/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NCNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NCNA
Valuation Measures
Market Cap
7.98M
Enterprise Value
-7.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.62
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.30
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.16%
Return on Equity (ttm)
-103.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-27.63M
Diluted EPS (ttm)
-16.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
17.23M
Total Debt/Equity (mrq)
2.66%
Levered Free Cash Flow (ttm)
-16.88M